Alvogen launches its generic Suboxane in the US

Alvogen has launched its generic equivalent to Indivior UK LLC’s Suboxone sublingual film (buprenorphine hydrochloride/naloxone hydrochloride) in the U.S.

Lisa Graver, President of Alvogen Americas, said this is an important product and she sees it as help for patients suffering from opioid dependence.

“The launch demonstrates a significant commitment from our teams to bringing affordable generic medicines to the market,” she said in the statement.

Suboxone sublingual film is indicated for treatment of opioid dependence. U.S. sales for Suboxone were approximately $1.1 billion in 2018, based on Indivior SEC Filings, the company noted.

Alvogen pointed out in the press release that it currently has 75 products in development and pending FDA approval for the U.S. market, with annual brand sales for filed products and those under development have current brand sales exceeding $35 billion, according to IMS IQVIA (2018).